Termeer Foundation Expands Leadership Team to Foster Ongoing Support and Recognition of Future Industry Leaders

Former Clinton Foundation Executive and Veteran Academic and Institutional Leader, Catharine C. Smith, Joins Termeer Foundation as Executive Director

BOSTON, March 29, 2021 -- The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced the appointment of Catharine C. Smith as the organization’s Executive Director, effective March 29, 2021. Ms. Smith brings extensive leadership experience to this position which includes nearly 20 years in foundations, academic settings, and organizations focused on healthcare innovation and transformation. As part of the Termeer Foundation’s executive leadership team she will be responsible for a myriad of functions including business strategy, fundraising, program development, partnerships, donor relations, and outreach.

At the heart of the Termeer Foundation is the Henri Termeer Network comprised of some of the life science industry’s most promising future company leaders; all of whom are working with the single purpose of developing medicines that one day will treat patients and potentially cure diseases. This emerging group of young professionals – the Henri Termeer Fellows – are supported by a collection of committed and established biotechnology executives who serve as Mentors to the Fellows and offer their expertise in a host of business areas.

“I am thrilled to welcome Catharine to the Foundation’s executive leadership team at such an opportune time of activity and growth for the organization,” said Belinda Termeer, President, Co-Founder and Member of the Board of Directors, The Termeer Foundation. “Catharine’s broad and diverse experience spans all professional areas of impact from research and operations, to business development and fundraising. Her perspective will be a timely asset to the Foundation as we continue to advance a broader program portfolio to a growing audience of industry entrepreneurs and established leaders.”

“It is an honor to join the Termeer Foundation and help continue the legacy and work of one of the industry’s most influential leaders, Henri Termeer, “said Ms. Smith. “In a brief time, the Foundation’s singular focus of identifying and championing future biotechnology executives has been instrumental in helping to maintain a continuity and consistency of companies positioned to meet the needs of patients. I am impressed with this commitment and the wealth of opportunities and innovative programming it affords these future leaders.”

Ms. Smith joins the Termeer Foundation from the Clinton Foundation where she served as Chief Executive Officer, Clinton Health Matters Initiative. In this role she led strategy development and national partnerships focusing on community-based solutions to the opioid crisis. Prior to the Clinton Foundation, Ms. Smith held leadership positions at Harvard Medical School (Executive Director, Center for Primary Care) and the Society of Hospital Medicine (VP, Quality & Education Programs). Ms. Smith’s areas of responsibility have included research management, finance, marketing, budgeting, leadership development and mentoring, organizational planning, national and global partnerships and digital learning. Ms. Smith holds a Masters in Business Administration from the Massachusetts Institute of Technology.

About The Termeer Foundation
Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation.

Contact:
Paul Kidwell
Termeer Foundation
617-680-1088
This email address is being protected from spambots. You need JavaScript enabled to view it.

The Termeer Foundation Launches Henri Termeer Transatlantic Connections Award

Annual honor to recognize young life science entrepreneurs in Massachusetts and the Netherlands; fostering relationships between the two biotechnology sectors

BOSTON, December 8, 2020 -- The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced the creation of The Henri Termeer Transatlantic Connections Award. The Award is part of an agreement signed in July 2019 between the Massachusetts Office of International Trade and Investment and the Dutch Ministry of Economic Affairs and Climate Policy, which created and signed a Memorandum of Understanding laying the basis for a Massachusetts – Netherlands Transatlantic Life Sciences Partnership. The signatories included Top Sector Life Sciences & Health (Health~Holland), MassBio, HollandBIO and the Henri A. Termeer Tribute Committee; all of whom agreed to provide support and organize activities to promote trans-Atlantic collaboration between the two biotechnology ecosystems.

“The establishment of the Henri Termeer Transatlantic Connections Award is the first of many partnerships this group plans to create that will help foster a strong relationship between life science communities in the Netherlands and Massachusetts,” said Belinda Termeer, President, Co-Founder and Member of the Board of Directors, The Termeer Foundation. “As a native of Holland, Henri was always interested in establishing working relationships with his homeland and his new business home in Cambridge. We are delighted at the creation of this award and feel that it will provide an excellent platform for identifying future industry ambassadors and the opportunity for collaborations between these two important life science sectors.”

The Henri Termeer Transatlantic Connections Award will be an annual award competition for life science entrepreneurs in the Netherlands and Massachusetts. Each year the Termeer Foundation and Health-Holland will select two young life science entrepreneurs, one in Massachusetts and one in the Netherlands, who are leading innovative biomedical research activities, and whose programs have the potential to strengthen transatlantic relations between the two life science regions. Candidates should have already established themselves within the life science industry leading an early-stage company, with a concrete business plan and initial funding in place. Additionally, the recipient will be someone interested in becoming actively involved in mentorship and who agrees to be involved in Termeer Foundation programs. Awardees receive Fellowship status within The Termeer Foundation, which includes access to experienced healthcare mentors, networking with fellow peer entrepreneurs, and recognition at The Termeer Foundation Annual Dinner. Recipients will also have the opportunity to spend a week visiting their fellow awardee’s company, and to participate in additional learning, networking and cultural events.

The winners of the 2021 Henri Termeer Transatlantic Connections Award will be announced at the end of April, 2021. Nominations should be submitted here.

“Life science research is increasingly developing into a global experience with partnerships between companies in diverse global locations becoming part of our industry’s DNA,” said Hans Schikan, board member of Health-Holland and a member of the Henri Termeer Transatlantic Connections Award Steering Committee. “One of the many important elements of the biotechnology business I learned from Henri Termeer during my time at Genzyme and as CEO of Prosensa, with Henri as an inspiring mentor, was the notion of understanding the needs of patients everywhere and applying our research in the development of treatments to address those needs no matter the location.” Members of the Massachusetts – Netherlands Transatlantic Life Sciences Partnership Steering Committee include: Belinda Termeer (Co-Founder and Member of the Board of Directors, The Termeer Foundation), Alan Walts (Treasurer, Secretary, Mentor, Co-Founder and Member of the Board of Directors, The Termeer Foundation), Hans Schikan (Member Board of Directors, Health-Holland), Bob Coughlin (President/CEO, Massachusetts Biotechnology Council), Clémence Ross-van Dorp (Ambassador Life Sciences & Health Sector), Annemiek Verkamman (Managing Director, HollandBIO), John Maraganore (CEO and Director, Alnylam Pharmaceuticals), and Daniel de Boer (Founder and Chief Executive Officer, ProQR Therapeutics).

“I am delighted to support this award that will provide an incredible opportunity each year for two deserving life science entrepreneurs,” said Daniel de Boer, Founder and Chief Executive Officer of ProQR Therapeutics. “Reflecting on my personal experience, Henri’s influence has been invaluable and he was instrumental in helping me to navigate my entrance into the biotechnology industry as a CEO. We co-founded ProQR together, which is now based in the Netherlands and Massachusetts, embodying the spirit of this initiative and his legacy.”

About The Termeer Foundation
Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation.

Contact:
Paul Kidwell
Termeer Foundation
617-680-1088
This email address is being protected from spambots. You need JavaScript enabled to view it.

Henri A. Termeer Square Officially Dedicated in Cambridge

Public Installation Honors Legacy and Contribution of Biotechnology Industry Pioneer

Life-sized sculpture of Henri Termeer Unveiled as Square Centerpiece

CAMBRIDGE, Mass.—December 4, 2020, --The Henri A. Termeer Tribute Committee along with the Termeer Foundation, today announced the completion and dedication of the Henri A. Termeer Square. Located in the heart of Cambridge’s Kendall Square, the public space was created to honor Henri Termeer who was a founding father of the biotechnology industry, and long-time CEO of Genzyme Corporation. Mr. Termeer unexpectedly passed away on May 12, 2017 at the age of 71.

Information on the Henri A. Termeer Square project and dedication can be found here.

“I am amazed how all the elements of the project have come together to form a beautiful visual experience,” said Belinda Termeer, President of The Termeer Foundation. “The dedication of the Henri A. Termeer Square and the public unveiling of his statue is a testimony to all of the many people and organizations who took part in this development and worked together to create this beautiful public space. I would like to extend my heartfelt gratitude to everyone for turning my daughter’s vision into a reality. Having her Dad’s statue as a touchstone in this community will keep his spirit alive. His statue feels at home here. The Termeer Foundation would like to thank all who contributed to this project in continuing Henri’s legacy.”

The Square is located at the former Kendall Square North location and adjacent to the one-time Genzyme headquarters. The site includes a rolling lawn, a fountain that runs into a shallow, reflecting “Giving Tree” pool, around which there is inscribed a quote from Henri Termeer. A sitting area for visitors near the fountain includes a life-size and life-like sculpture of Henri Termeer seated as if in conversation and offering advice to a colleague; a common occurrence for him. The statue was created by renowned sculptor Pablo Eduardo who was commissioned by the Tribute Committee to create a sculpture of Henri to serve as a lasting remembrance of his tireless support for patients, next generation leaders and the community.

“The Henri A. Termeer Square is a wonderful and lasting remembrance to Henri’s legacy and his pervasive impact on the biotechnology industry, said John Maraganore, CEO of Alnylam Pharmaceuticals and Termeer Tribute Co-Chair. “Henri not only redefined how all companies approach their work and relationships with patients, particularly those with rare genetic diseases, but he was also a gifted mentor who touched and inspired scores of future biotechnology leaders with his astute guidance and insight.”

“Henri will be long-remembered for his incredible impact on the local Cambridge biotechnology sector as well as being a catalyst for global advancements in rare diseases, an area historically untouched by our industry before he and Genzyme transformed this therapeutic area into opportunities for patients,” said Robert Coughlin, President and CEO of MassBio and Termeer Tribute Co-Chair. “The many accomplishments of Henri and his extraordinary leadership have been strongly linked to the growth we have achieved as a biotech sector. I am delighted to have this beautiful space in the heart of Kendall Square serve as a reminder of his impact and the spirit with which he influenced this community.”

The Henri A. Termeer Committee guided the project since its 2018 groundbreaking and recent 2020 completion. The Committee included representatives from Alnylam Pharmaceuticals, MassBio, MassBioEd, BioMed Realty, and the Termeer Foundation and Family. Stantec Inc. designed the Square and was led by Bob Corning. Construction was done by Suffolk Construction and the project was managed by Kevin Pessolano, Coffey Design + Build.

“Henri was a friend and mentor to so many of us but, more importantly, he set a new standard for social equity in healthcare,” said Bill Kane, Executive Vice President, East Coast and UK Markets. “Thanks to the extraordinary vision of Belinda and Adriana Termeer, Pablo Eduardo, and Stantec, Termeer Square memorializes Henri’s legacy in a very special way and encourages the general public to think about his values.”

The Henri A. Termeer Square was privately financed and a select group of biopharmaceutical companies supported this project as Visionary Sponsors. Those organizations include: Alnylam Pharmaceuticals, Sanofi Genzyme, Takeda Pharmaceuticals, Biogen, Ipsen and the Termeer Family. Additionally, there were a strong contingent of private donors who also offered their support.

About Henri Termeer
Henri A. Termeer was a former Chairman, President and CEO of Genzyme Corporation for nearly three decades prior to its acquisition by the French drug maker Sanofi. Henri unexpectedly passed away on May 12, 2017 at the age of 71. He was known for his service to the rare disease community and his unsurpassed entrepreneurial leadership that spurred the rise of an industry dedicated to innovative treatments for orphan diseases. Under his stewardship Genzyme grew from a modest entrepreneurial venture to one of the world's leading biotechnology companies and a pioneer of some of the first treatments for rare genetic diseases. He is widely regarded as one of the founders of Boston's booming biotech industry. In addition to his entrepreneurial engagements, Henri was a beloved mentor and an avid philanthropist.

About The Termeer Foundation
Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation.

###

Contact:

Paul Kidwell
Termeer Foundation
617-680-1088

The Termeer Foundation Expands Board of Directors

BOSTON, October 15, 2020 -- The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced the expansion of its Board of Directors. The foundation added Gail Maderis, President and CEO of Antiva Biosciences; John Maraganore, CEO and Director at Alnylam Pharmaceuticals; and Joan Reede, M.D., Dean for Diversity and Community Partnership at Harvard Medical School to the board.

“We are honored to have Gail Maderis, John Maraganore and Joan Reede join The Termeer Foundation Board of Directors and help us advance our vision of connecting the world of healthcare innovators until every patient has a cure,” said Belinda Termeer, President and Co-Founder of The Termeer Foundation. “Their combined expertise spanning entrepreneurship, organizational leadership, mentoring, diversity and strategy will be instrumental in helping us build this foundation.”

Gail Maderis currently serves as President and CEO of Antiva Biosciences and as a member of the Board of Directors at Valitor Inc., the Biotechnology Innovation Organization (BIO), and the California Life Sciences Institute. She is also a Trustee of the University of California Berkeley Foundation. Gail has over 20 years of leadership experience in biopharmaceutical companies, including at Genzyme Corporation, where she worked closely with Henri Termeer. Previously, Gail led BayBio, the industry organization representing and supporting Northern California’s life science community. She also previously served as President and CEO of Five Prime Therapeutics, Inc., and held senior executive positions at Genzyme, including Founder and President of Genzyme Molecular Oncology (GZMO). Gail also practiced management and strategy consulting with Bain & Co. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.

John Maraganore serves as CEO and Director at Alnylam Pharmaceuticals, Chair of the Board for Agios Pharmaceuticals, co-chair of the Termeer Tribute Committee, and member of the Biotechnology Industry Organization (BIO) Executive Committee. John brings The Termeer Foundation extensive experience gained from building and managing the translation of RNAi from a Nobel Prize-winning discovery into an innovative, entirely new class of medicines, and in the process creating one of the biopharmaceutical industry’s largest and arguably most successful companies. John has served as the CEO and a Director of Alnylam since 2002. Prior to Alnylam, John served as an officer and a member of the management team for Millennium Pharmaceuticals, and prior to that he held various positions at Biogen, where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOG™ and currently marketed by The Medicines Company. Prior to Biogen, John was a scientist at ZymoGenetics, Inc., and the Upjohn Company. John also formerly served as Chair of the Board of Directors for the Biotechnology Innovation Organization (BIO). John received his MS and PhD in biochemistry and molecular biology at the University of Chicago.

Joan Reede, M.D., serves as Dean for Diversity and Community Partnership at Harvard Medical School, and President of the Biomedical Science Careers Program. Joan brings to The Termeer Foundation a lifelong passion for and experience with mentoring and supporting diversity in the biosciences. She is Harvard Medical School’s first Dean for Diversity and Community Partnership, responsible for the development and management of a comprehensive program that provides leadership, guidance, and support to promote the increased recruitment, retention, and advancement of underrepresented minority faculty. She also serves in a number of other positions, including Faculty Director of Community Outreach at HMS, Professor at HMS and at Harvard’s Chan School of Public Health, and Assistant in Health Policy at Massachusetts General Hospital. While at HMS, Joan created more than 20 diversity and leadership-focused programs, including founding the HMS Minority Faculty Development Program and the Biomedical Careers Program. Before joining Harvard, she served as the medical director of a Boston community health center and worked as a pediatrician in community and academic health centers, juvenile prisons, and public schools. She has held a number of advisory roles including serving on the Health and Human Services Advisory Committee on Minority Health and the Secretary’s Advisory Committee to the Director of NIH. Joan graduated from Brown University and Mount Sinai School of Medicine. She holds an MPH and an MS in Health Policy Management from Harvard T. H. Chan School of Public Health, and an MBA from Boston University.

Also joining The Termeer Foundation as a Board Observer is Adriana Termeer. The new appointees join existing board members Belinda Termeer and Alan Walts, Treasurer, Secretary, Mentor and Co-Founder of The Termeer Foundation and Venture Partner with Advent Life Sciences.

About The Termeer Foundation

Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation.

 

Contact:

Paul Kidwell

Termeer Foundation

617-680-1088

This email address is being protected from spambots. You need JavaScript enabled to view it.

The Termeer Foundation Awards Fellowships for 2020 and Opens 2021 Application Process


The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced the recipients of the Henri Termeer Fellowship for 2020 and opened its application process for 2021.

The Henri Termeer Fellowship is awarded each year to up-and-coming company founders, CEOs or heads of life science organizations who are working to bring life-changing treatments to patients. Recipients are often early in their leadership career trajectory, such as first-time CEOs, and place a high priority on connectivity, community, mentoring, and seeing the value in other people from all walks of life. Fellows receive membership in The Henri Termeer Network, an ever-expanding group of emerging and established healthcare leaders who pool their collective experience to advance cures. Additional Fellowship benefits include quarterly mentor presentations, monthly peer-to-peer learning presentations, individual 1:1 mentoring, and access to other events and initiatives sponsored by The Termeer Foundation.

“The Henri Termeer Fellowship Program is inspired by Henri, who was deeply committed to supporting and mentoring life science professionals. Henri was actively mentoring nearly 50 CEOs at the time of his passing and coached hundreds more throughout the course of his career,” said Belinda Termeer, President of The Termeer Foundation. “The Termeer Foundation believes many healthcare challenges can be solved through the mentoring, support, communication and shared experience provided through our network.”

The 2020 Henri Termeer Fellows

Hasan Celiker, Xeno Biosciences

Hasan is the founder and CEO of Xeno Biosciences, a biopharmaceutical company developing novel therapeutics for obesity and related metabolic diseases. He previously worked as a consultant at start-up companies in diverse technology areas such as synthetic biology, nanotechnology to agriculture. He earned his Ph.D. at MIT in Electrical Engineering & Computer Science and completed doctorate work on the evolution of cooperation and interspecies interactions in microbial ecosystems.

Tim Knotnerus, AgomAb Therapeutics

Tim is CEO of AgomAb Therapeutics, a privately held Belgian based biotech company developing hepatocyte growth factor (HGF) mimetic antibodies. While the company’s antibodies maintain the full therapeutic potential of HGF, they display the excellent drug-like properties of antibodies, holding the promise for regeneration of tissues in a variety of clinical indications. In March 2019, the team closed a $23 million series A financing round from a syndicate of venture capital and strategic investors to fund the non-clinical development of the lead compound. Prior to AgomAb, Tim was VP Corporate Development at AM-Pharma where he and the team conducted a phase IIb trial in patients with sepsis-associated acute kidney injury, signed a $600M option-to-acquisition deal with Pfizer and raised a $133M private financing round. Prior to that, Tim was a senior associate at Aescap Venture, a venture capital fund investing in European medical companies. Tim holds an executive MBA from IMD (Switzerland), where he was named Valedictorian, and gained a Science and Innovation Masters and a Drug Innovation Masters, both with honors from Utrecht University (NL).

 Natalie Yivgi Ohana, Minovia Therapeutics

Natalie the scientific founder and CEO of Minovia Therapeutics, a clinical-stage biotechnology company focused on developing innovative cell therapies for mitochondrial diseases. She received her Ph.D. in Biochemistry from The Hebrew University and performed her postdoctoral fellowship at the Weizmann Institute of Science. She has over twenty years’ experience in mitochondrial research and currently leads the global organization in Israel, the U.S. and Switzerland.

Stan Wang M.D., Ph.D., Thymmune Therapeutics

Stan is founder and CEO of Thymmune Therapeutics, an innovative cell therapy company working to address high unmet needs across immunology. Previously, Stan was Founding Chief Scientific Officer at Cellino Biotech, where he led R&D and application of its technology to rapidly engineer cells. Stan received his Ph.D. from the University of Cambridge and his M.D. from Columbia University. He was a postdoctoral fellow in cell and gene therapy with George Church at Harvard Medical School.

Minmin (Mimi) Yen, PhagePro

Mimi is CEO and Co-Founder of PhagePro, an early-stage biotechnology therapeutics company that develops bacteriophage-based products to help the world’s most vulnerable communities. Previously Mimi earned her Ph.D. in microbiology at Tufts University and completed research on cholera in the Camilli Lab. She also pursued a Master's in Public Health at Boston University, specializing in Program Management and Global Health.

Applications are now open for the Henri Termeer Fellows class of 2021 and will be accepted through December 31, 2020. Apply online at www.termeerfoundation.org. Applications are reviewed by The Termeer Foundation Board of Directors and a rotating group of Mentor volunteers. Notifications will be sent out in the first quarter of 2021. The Termeer Foundation is committed to ensuring the inclusiveness of its Fellowship program, particularly in recognition of the underrepresentation of women and Black, Brown and Indigenous People of Color at the CEO level within the biopharmaceutical industry.

 

About The Termeer Foundation

Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us on LinkedIn @TermeerFoundation.

 

Contact:
Lorie Umanita
Termeer Foundation
617-977-4054
This email address is being protected from spambots. You need JavaScript enabled to view it.


termeer logo bottom